Skip to content
Screener

Acadia Pharmaceuticals ACAD Q3 2025 earnings

Reported November 5, 2025 · After market close

Revenue$278.6MMiss by $14.0M
EPS$0.26Beat by $0.12
Revenue estimate$292.6M
EPS estimate$0.14

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$332.3M
EPS estimate$0.21

Financials

Q3 2025

Income statement

See full
Revenue$278.6M+11.3%
Gross profit$257.0M+11.0%
Operating income$35.8M+13.0%
Net income$71.8M+119%
EPS (diluted)$0.42+110%

Balance sheet

See full
Cash & equivalents$258.0M+66.3%
Total debt$54.8M+11.0%
Total equity$917.3M+58.9%
Total assets$1.3B+36.2%

Cash flow

See full
Operating cash flow$74.3M+17.5%
CapEx$388.0K+454%
Free cash flow$73.9M+17.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$3.6B+41.1%
Enterprise value$3.4B+38.9%
P/E13.8×-6.1×
P/S3.4×+0.7×

Profitability

See full
Gross margin91.9%+0.3pp
Operating margin23%—
Net margin24.9%+11.1pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity35%+7.6pp
Debt / equity0.1×0.0×
Current ratio3×+0.7×

Segments

By product

See full
Nuplazid$177.5M+11.5%
Daybue$101.1M+10.8%

By segment

See full
Reportable Segment Aggregation Before Other Operating$278.6M+11.3%

FAQ

When did Acadia Pharmaceuticals report Q3 2025 earnings?
Acadia Pharmaceuticals (ACAD) reported Q3 2025 earnings on November 5, 2025 after market close.
What were Acadia Pharmaceuticals's Q3 2025 revenue and EPS?
Acadia Pharmaceuticals reported revenue of $278.6M and eps of $0.26 for Q3 2025.
Did Acadia Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $292.6M by $14.0M. EPS beat the consensus estimate of $0.14 by $0.12.
How did Acadia Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.3% from $250.4M a year earlier and eps grew 30.0% from $0.20.
Where can I find Acadia Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-262610) and the 10-Q periodic report (0001193125-25-267453) directly on SEC EDGAR. The filing index links above go to sec.gov.